百克生物-688276.SH-公司年報(bào)點(diǎn)評(píng)

公司研究/醫(yī)藥與健康護(hù)理公司研究/醫(yī)藥與健康護(hù)理百克生物（688276）公司年報(bào)點(diǎn)評(píng)證券研究報(bào)告投資要點(diǎn)：投資要點(diǎn)：事件：公司公告22318.25億元（0.30，歸母凈利潤(rùn)5.01（75.984.93（195.810個(gè)月，2023年公司針對(duì)部分預(yù)計(jì)無(wú)法實(shí)現(xiàn)銷售的5205萬(wàn)元，同時(shí)該部分對(duì)應(yīng)合同履約成本153Q45.81（182.6，歸母凈利潤(rùn)1.0（661.7，扣非歸母凈利潤(rùn)1.8億元（604.0。202314.36%12工作，以期彌補(bǔ)兒童市場(chǎng)的不足；同時(shí)，積極推進(jìn)水痘疫苗產(chǎn)品出口工作，20231.226.85%，全年公司對(duì)流感疫苗的排產(chǎn)更加謹(jǐn)慎合理，生產(chǎn)量和庫(kù)存量同比減少，我們預(yù)計(jì)后續(xù)減值風(fēng)險(xiǎn)較小。23M166.358.83億元。公司充分利用深入終端的市場(chǎng)營(yíng)銷網(wǎng)絡(luò)和專業(yè)高效的市場(chǎng)服務(wù)提升品牌影響力，同時(shí)數(shù)字化營(yíng)銷模式初具成果，截至23年底，帶狀皰疹疫苗已有效覆蓋全國(guó)近三分之一接種點(diǎn)，預(yù)計(jì)24年接種點(diǎn)覆蓋率將持續(xù)增加。持續(xù)推進(jìn)創(chuàng)新發(fā)展戰(zhàn)略，五大核心技術(shù)平臺(tái)覆蓋人用疫苗研發(fā)和產(chǎn)業(yè)化的全20231.9923（液體劑型）Pre-NDAIIII期臨床研究；二倍體狂苗以及破傷風(fēng)單抗的臨床試驗(yàn)申請(qǐng)已獲得批準(zhǔn)，即將開(kāi)展臨床研究；佐劑流感疫苗、重組帶狀皰疹疫苗、mRNAHib2024年開(kāi)展臨床試驗(yàn)申報(bào)工作；RSV疫苗及抗體、阿爾茨海默病治療性疫苗等多個(gè)研發(fā)項(xiàng)目的臨床前研究工作。盈利預(yù)測(cè)：2024-2026EPS元。公司的水痘疫苗和鼻噴流感疫苗的1.0XPE帶皰疫苗正處于放量期，對(duì)應(yīng)目標(biāo)價(jià)54.13元，給予優(yōu)于大市”評(píng)級(jí)。202220232024E2025E202220232024E2025E2026E營(yíng)業(yè)收入（百萬(wàn)元）10711825234528123333(+/-)YoY(%)-10.9%70.3%28.5%19.9%18.5%凈利潤(rùn)（百萬(wàn)元）1825016848821081(+/-)YoY(%)-25.5%176.0%36.5%29.0%22.5%全面攤薄EPS(元)0.441.211.662.142.62毛利率(%)87.2%90.2%90.1%90.8%91.5%凈資產(chǎn)收益率(%)5.1%12.5%14.5%15.8%16.2%（22222TI備注：凈利潤(rùn)為歸屬母公司所有者的凈利潤(rùn)公司是一家主要致力于傳染病防治的創(chuàng)新生物醫(yī)藥企業(yè),是國(guó)家級(jí)高新技術(shù)企業(yè)。公司目前已有水痘疫苗、狂犬疫苗以及凍干鼻噴流感疫苗三種已獲批的疫苗產(chǎn)品，主要包括帶狀皰疹減毒活疫苗、吸附無(wú)細(xì)胞百白破(三組分)聯(lián)合疫苗、b型流感嗜血桿菌結(jié)合疫苗、全人源抗狂犬病單克隆抗體、全人源抗破傷風(fēng)毒素單克隆抗體等。公司具有完備的創(chuàng)新研發(fā)體系，重視創(chuàng)新環(huán)境的建設(shè)和新產(chǎn)品的開(kāi)發(fā)，與國(guó)內(nèi)外研發(fā)機(jī)構(gòu)長(zhǎng)期保持著緊密的科研協(xié)作關(guān)系。公司承接了多項(xiàng)國(guó)家級(jí)研發(fā)項(xiàng)目，其中包括牽頭國(guó)家科技重大專項(xiàng)：長(zhǎng)春百克多肽藥物和創(chuàng)新疫苗孵化基地建設(shè)(課題編號(hào)2011ZX09401-025)、重組疫苗通用載體構(gòu)建與應(yīng)用技術(shù)平臺(tái)2014ZX09304314)1項(xiàng)：創(chuàng)新藥物孵化(吉林)基地(2011ZX09401-305-06)；亦有多項(xiàng)在研項(xiàng)目獲得國(guó)家科技資金支持。附表前十大股東：股東名稱占總股本比例(%)長(zhǎng)春高新技術(shù)產(chǎn)業(yè)(集團(tuán))股份有限公司41.5400孔維25.2500魏學(xué)寧5.7700余盛2.2600胡尚書(shū)2.0300陳曉輝1.5000全國(guó)社?；鹨灰话私M合1.0000吉林省乾亨投資合伙企業(yè)(有限合伙)0.7900王紅0.7900長(zhǎng)春新區(qū)產(chǎn)業(yè)基金投資有限公司0.7000合 計(jì)81.6300財(cái)務(wù)報(bào)表分析和預(yù)測(cè)主要財(cái)務(wù)指標(biāo)20232024E2025E2026E利潤(rùn)表（百萬(wàn)元）20232024E2025E2026E每股指標(biāo)（元）營(yíng)業(yè)總收入1825234528123333每股收益1.211.662.142.62營(yíng)業(yè)成本178233258284每股凈資產(chǎn)9.7411.4013.5316.15毛利率%90.2%90.1%90.8%91.5%每股經(jīng)營(yíng)現(xiàn)金流0.621.031.702.02營(yíng)業(yè)稅金及附加13212529每股股利0.150.000.000.00營(yíng)業(yè)稅金率%0.7%0.9%0.9%0.9%價(jià)值評(píng)估（倍）營(yíng)業(yè)費(fèi)用6478329901167P/E35.0225.6619.8916.23營(yíng)業(yè)費(fèi)用率%35.5%35.5%35.2%35.0%P/B4.363.733.142.63管理費(fèi)用159199239283P/S9.627.486.245.26管理費(fèi)用率%8.7%8.5%8.5%8.5%EV/EBITDA32.9519.6314.9611.82EBIT5757719901206股息率%0.4%0.0%0.0%0.0%財(cái)務(wù)費(fèi)用-12-6-12-22盈利能力指標(biāo)（%）財(cái)務(wù)費(fèi)用率%-0.7%-0.3%-0.4%-0.7%毛利率90.2%90.1%90.8%91.5%資產(chǎn)減值損失-55-35-20-20凈利潤(rùn)率27.5%29.2%31.4%32.4%投資收益1181凈資產(chǎn)收益率12.5%14.5%15.8%16.2%營(yíng)業(yè)利潤(rùn)5597719961222資產(chǎn)回報(bào)率9.9%11.6%12.7%13.3%營(yíng)業(yè)外收支4666投資回報(bào)率12.6%14.4%15.5%15.9%利潤(rùn)總額56477710021228盈利增長(zhǎng)（%）EBITDA67485210741291營(yíng)業(yè)收入增長(zhǎng)率70.3%28.5%19.9%18.5%所得稅6393120147EBIT增長(zhǎng)率206.5%34.0%28.5%21.8%有效所得稅率%11.1%12.0%12.0%12.0%凈利潤(rùn)增長(zhǎng)率176.0%36.5%29.0%22.5%少數(shù)股東損益0000償債能力指標(biāo)資產(chǎn)負(fù)債率20.3%20.5%19.4%18.2%歸屬母公司所有者凈利潤(rùn)5016848821081流動(dòng)比率2.212.633.163.72速動(dòng)比率1.982.392.933.51資產(chǎn)負(fù)債表（百萬(wàn)元）20232024E2025E2026E現(xiàn)金比率0.440.691.131.57貨幣資金44283415092309經(jīng)營(yíng)效率指標(biāo)應(yīng)收賬款及應(yīng)收票據(jù)1567202624042847應(yīng)收賬款周轉(zhuǎn)天數(shù)249.78275.55283.60283.55存貨199247250263存貨周轉(zhuǎn)天數(shù)395.04344.89345.98325.05其它流動(dòng)資產(chǎn)36495460總資產(chǎn)周轉(zhuǎn)率0.390.430.440.44流動(dòng)資產(chǎn)合計(jì)2245315642165479固定資產(chǎn)周轉(zhuǎn)率2.302.402.933.55長(zhǎng)期股權(quán)投資35353535固定資產(chǎn)984967949929在建工程1101110111011101無(wú)形資產(chǎn)347322297272現(xiàn)金流量表（百萬(wàn)元）20232024E2025E2026E非流動(dòng)資產(chǎn)合計(jì)2802276027172672凈利潤(rùn)5016848821081資產(chǎn)總計(jì)5046591669338150少數(shù)股東損益0000短期借款20202020非現(xiàn)金支出186137118120應(yīng)付票據(jù)及應(yīng)付賬款17262932非經(jīng)營(yíng)收益-34-6-14-6預(yù)收賬款0000營(yíng)運(yùn)資金變動(dòng)-397-389-286-360其它流動(dòng)負(fù)債977115412861420經(jīng)營(yíng)活動(dòng)現(xiàn)金流255425701834流動(dòng)負(fù)債合計(jì)1015120013351472資產(chǎn)-471-34-34-34長(zhǎng)期借款0000投資-168000其它長(zhǎng)期負(fù)債11111111其他0181非流動(dòng)負(fù)債合計(jì)11111111投資活動(dòng)現(xiàn)金流-639-34-25-33負(fù)債總計(jì)1026121113461483債權(quán)募資20000實(shí)收資本413413413413股權(quán)募資0000歸屬于母公司所有者權(quán)益4020470555876667其他-63000少數(shù)股東權(quán)益0000融資活動(dòng)現(xiàn)金流-42000負(fù)債和所有者權(quán)益合計(jì)5046591669338150現(xiàn)金凈流量-425392675801（4月8（）（22，TIAPPENDIX1SummaryInvestmentHighlights:Event:TheCompanyannouncedits2023annualreport,achievingaRevenueofRMB1.825billion(up70.30%),netprofitattributabletoshareholdersofRMB501million(up175.98%),andrecurringNPAtSofRMB493million(up195.86%).Duetothe10-monthshelflifeofthenasalsprayfluvaccine,theCompanymadeaprovisionforimpairmentofRMB52.05millionforinventoryexpectednottobesold,andRMB1.53millionforcorrespondingcontractfulfillmentcosts-logisticsandwarehousingcosts.InQ4alone,RevenuewasRMB581million(up182.65%),netprofitattributabletoshareholderswasRMB170million(up661.07%),andrecurringNPAtSwasRMB168million(up604.01%).Varicellavaccineexportsincreased,andnasalsprayfluvaccinesalesremainedstable.In2023,varicellavaccineRevenuewasRMB820million,aYoYdecreaseof14.36%.Duetofactorssuchasthedeclineinthedomesticbirthrate,domesticsalesoftheproductdecreased.TheCompanywillstrivetostabilizethedomesticmarketpositionofthevaricellavaccine,promoteittopeopleover12yearsoldtocompensateforthechildren’smarket,andactivelypushforvaccineexports,acceleratinginternationalregistrationandmarketdevelopment.ThenasalsprayfluvaccinegeneratedRevenueofRMB122million,aYoYincreaseof6.85%.TheCompanywasmorecautiousandreasonableinschedulingfluvaccineproduction,withbothproductionandinventorylevelsdecreasingYoY,andweexpectsubsequentimpairmentriskstobesmall.TheCompany’sdomesticallydevelopedherpeszostervaccineforpeopleover40wasapprovedinJanuary2023,obtainedbatchissuancecertificationinApril,andachievedaccessandsalesinvariousplacesthroughouttheyear,withasalesvolumeof663,500doses,correspondingtoRevenueofRMB883million.TheCompanyleverageditsin-depthterminalmarketingnetworkandprofessionalandefficientmarketservicestoenhancebrandinfluence,anditsdigitalmarketingmodelshowedinitialsuccess.Bytheendof2023,theherpeszostervaccinehadeffectivelycoverednearlyone-thirdofthevaccinationpointsnationwide,withthecoveragerateexpectedtocontinueincreasingin2024.TheCompanycontinuestoadvanceitsinnovationdevelopmentstrategy,withfivecoretechnologyplatformscoveringtheentireprocessofhumanvaccineR&Dandindustrialization.In2023,theCompany’sR&DinvestmentwasRMB199million.Asoftheendof2023,theCompany’sinfluenzavaccine(liquidform)wasinthePre-NDAstage,thecomponentpertussisvaccinewaspreparingforPhaseIIIclinicalsamples,andtherabiesmonoclonalantibodywasundergoingPhaseIclinicalresearch;clinicaltrialapplicationsfordiploidrabiesvaccineandtetanusmonoclonalantibodywereapprovedandabouttostartclinicalresearch;adjuvantedinfluenzavaccine,recombinantherpeszostervaccine,HSV-2mRNAvaccine,andHibvaccineplanstostartclinicaltrialapplicationsin2024;meanwhile,theCompanyisactivelyadvancingpreclinicalresearchonRSVvaccinesandantibodies,Alzheimer’sdiseasetherapeuticvaccines,andseveralotherR&Dprojects.EarningsForecast:WeexpecttheCompanytoachievenetprofitattributabletoshareholdersofRMB684/882/1081millionfor2024-2026,withcorrespondingEPSofRMB1.66/2.14/2.62.TheCompany’svaricellaandnasalsprayfluvaccinesalesarebasicallystable,andtheherpeszostervaccinefillsadomesticgapwithsignificantpotential.WegivetheCompanya2024targetpriceofRMB54.13,withan“Outperform”rating.RiskWarning:Risksofweakerthanexpectedproductsales,andrisksofnewproductR&Dprogressfallingshortofexpectations.附錄APPENDIX重要信息披露本研究報(bào)告由海通國(guó)際分銷，海通國(guó)際是由海通國(guó)際研究有限公司(HTIRL)，HaitongSecuritiesIndiaPrivateLimited(HSIPL)，HaitongInternationalJapanK.K.(HTIJKK)和海通國(guó)際證券有限公司(HTISCL)的證券研究團(tuán)隊(duì)所組成的全球品牌，海通國(guó)際證券集團(tuán)(HTISG)各成員分別在其許可的司法管轄區(qū)內(nèi)從事證券活動(dòng)。IMPORTANTDISCLOSURESThisresearchreportisdistributedbyHaitongInternational,aglobalbrandnamefortheequityresearchteamsofHaitongInternationalResearchLimited(“HTIRL”),HaitongSecuritiesIndiaPrivateLimited(“HSIPL”),HaitongInternationalJapanK.K.(“HTIJKK”),HaitongInternationalSecuritiesCompanyLimited(“HTISCL”),andanyothermemberswithintheHaitongInternationalSecuritiesGroupofCompanies(“HTISG”),eachauthorizedtoengageinsecuritiesactivitiesinitsrespectivejurisdiction.HTIRL分析師認(rèn)證AnalystCertification:我，孟科含，在此保證（i）本研究報(bào)告中的意見(jiàn)準(zhǔn)確反映了我們對(duì)本研究中提及的任何或所有目標(biāo)公司或上市公司的個(gè)人觀點(diǎn)，并且（ii）我的報(bào)酬中沒(méi)有任何部分與本研究報(bào)告中表達(dá)的具體建議或觀點(diǎn)直接或間接相關(guān)；及就此報(bào)告中所討論目標(biāo)公司的證券，我們（包括我們的家屬）在其中均不持有任何財(cái)務(wù)利益。我和我的家屬（我已經(jīng)告知他們）將不會(huì)在本研究3個(gè)工作日內(nèi)交易此研究報(bào)告所討論目標(biāo)公司的證券。I,KehanMengcertifythatitheviewsexpressedinthisresearchreportaccuratelyreflectmypersonalviewsaboutanyorallofthesubjectcompaniesorissuersreferredtointhisresearchandiinopartofmycompensationwas,isorwillbedirectlyorindirectlyrelatedtothespecificrecommendationsorviewsexpressedinthisresearchreportandthatIincludingmembersofmyhouseholdhavenofinancialinterestinthesecurityorsecuritiesofthesubjectcompaniesdiscussedIandmyhousehold,whomIhavealreadynotifiedofthis,willnotdealinortradeanysecuritiesinrespectoftheissuerthatIreviewwithin3businessdaysaftertheresearchreportispublished.利益沖突披露ConflictofInterestDisclosures海通國(guó)際及其某些關(guān)聯(lián)公司可從事投資銀行業(yè)務(wù)和/或?qū)Ρ狙芯恐械奶囟ü善被蚬具M(jìn)行做市或持有自營(yíng)頭寸。就本研究報(bào)告而言，以下是有關(guān)該等關(guān)系的披露事項(xiàng)（以下披露不能保證及時(shí)無(wú)遺漏，如需了解及時(shí)全面信息，請(qǐng)發(fā)郵件至ERD-Disclosure@）HTIandsomeofitsaffiliatesmayengageininvestmentbankingand/orserveasamarketmakerorholdproprietarytradingpositionsofcertainstocksorcompaniesinthisresearchreport.Asfarasthisresearchreportisconcerned,thefollowingarethedisclosuremattersrelatedtosuchrelationship(Asthefollowingdisclosuredoesnotensuretimelinessandcompleteness,pleasesendanemailtoERD-Disclosure@iftimelyandcomprehensiveinformationisneeded).評(píng)級(jí)定義（從2020年7月1日開(kāi)始執(zhí)行）：海通國(guó)際（以下簡(jiǎn)稱“HTI”）采用相對(duì)評(píng)級(jí)系統(tǒng)來(lái)為投資者推薦我們覆蓋的公HTI的評(píng)級(jí)定義。并且HTI發(fā)布分析師觀點(diǎn)的完整信息，投資者應(yīng)仔細(xì)閱讀全文而非僅看評(píng)級(jí)。在任何情況下，分析師的評(píng)級(jí)和研究都不能作為投資建議。投資者的買賣股票的決策應(yīng)基于各自情況（比如投資者的現(xiàn)有持倉(cāng)）以及其他因素。分析師股票評(píng)級(jí)優(yōu)于大市12-1810%以上，基準(zhǔn)定義如下中性12-18個(gè)月內(nèi)預(yù)期相對(duì)基準(zhǔn)指數(shù)變化不大，基準(zhǔn)定義如下。根據(jù)FINRA/NYSE的評(píng)級(jí)分布規(guī)則，我們會(huì)將中性評(píng)級(jí)劃入持有這一類別。弱于大市12-1810%以上，基準(zhǔn)定義如下各地股票基準(zhǔn)指數(shù)：日本–TOPIX,韓國(guó)–KOSPI,臺(tái)灣–TAIEX,印度–Nifty100,美國(guó)–SP500;其他所有中國(guó)概念股–MSCIChina.RatingsDefinitions(from1Jul2020):HaitongInternationalusesarelativeratingsystemusingOutperform,Neutral,orUnderperformforrecommendingthestockswecovertoinvestors.InvestorsshouldcarefullyreadthedefinitionsofallratingsusedinHaitongInternationalResearch.Inaddition,sinceHaitongInternationalResearchcontainsmorecompleteinformationconcerningtheanalyst'sviews,investorsshouldcarefullyreadHaitongInternationalResearch,initsentirety,andnotinferthecontentsfromtheratingalone.Inanycase,ratings(orresearch)shouldnotbeusedorrelieduponasinvestmentadvice.Aninvestor'sdecisiontobuyorsellastockshoulddependonindividualcircumstances(suchastheinvestor'sexistingholdings)andotherconsiderations.AnalystStockRatingsOutperform:Thestock’stotalreturnoverthenext12-18monthsis

評(píng)級(jí)分布RatingDistribution expectedtoexceedthereturnofitsrelevantbroadmarketbenchmark,asindicatedbelow.Neutral:Thestock’stotalreturnoverthenext12-18monthsisexpectedtobeinlinewiththereturnofitsrelevantbroadmarketbenchmark,asindicatedbelow.ForpurposesonlyofFINRA/NYSEratingsdistributionrules,ourNeutralratingfallsintoaholdratingcategory.Underperform:Thestock’stotalreturnoverthenext12-18monthsisexpectedtobebelowthereturnofitsrelevantbroadmarketbenchmark,asindicatedbelow.Benchmarksforeachstock’slistedregionareasfollows:Japan–TOPIX,Korea–KOSPI,Taiwan–TAIEX,India–Nifty100,US–SP500;forallotherChina-conceptstocks–MSCIChina.截至2023年12月31日海通國(guó)際股票研究評(píng)級(jí)分布優(yōu)于大市中性弱于大市(持有)海通國(guó)際股票研究覆蓋率 89.4%9.6%1.0%投資銀行客戶* 3.9%5.1%5.6%*在每個(gè)評(píng)級(jí)類別里投資銀行客戶所占的百分比。上述分布中的買入，中性和賣出分別對(duì)應(yīng)我們當(dāng)前優(yōu)于大市，中性和落后大市評(píng)級(jí)。只有根據(jù)FINRA/NYSE的評(píng)級(jí)分布規(guī)則，我們才將中性評(píng)級(jí)劃入持有這一類別。請(qǐng)注意在上表中不包含非評(píng)級(jí)的股票。此前的評(píng)級(jí)系統(tǒng)定義（直至2020年6月30日）：買入，未來(lái)12-18個(gè)月內(nèi)預(yù)期相對(duì)基準(zhǔn)指數(shù)漲幅在10%以上，基準(zhǔn)定義如下中性，未來(lái)12-18FINRA/NYSE的評(píng)級(jí)分布規(guī)則，我們會(huì)將中性評(píng)級(jí)劃入持有這一類別。賣出，未來(lái)12-18個(gè)月內(nèi)預(yù)期相對(duì)基準(zhǔn)指數(shù)跌幅在10%以上，基準(zhǔn)定義如下各地股票基準(zhǔn)指數(shù)：日本–TOPIX,韓國(guó)–KOSPI,臺(tái)灣–TAIEX,印度–Nifty100;其他所有中國(guó)概念股–MSCIChina.HaitongInternationalEquityResearchRatingsDistribution,asofDecember31,2023OutperformNeutralUnderperformHTIEquityResearchCoverage89.4%9.6%1.0%IBclients*3.9%5.1%5.6%*Percentageofinvestmentbankingclientsineachratingcategory.BUY,Neutral,andSELLintheabovedistributioncorrespondtoourcurrentratingsofOutperform,Neutral,andUnderperform.ForpurposesonlyofFINRA/NYSEratingsdistributionrules,ourNeutralratingfallsintoaholdratingcategory.PleasenotethatstockswithanNRdesignationarenotincludedinthetableabove.Previousratingsystemdefinitions(until30Jun2020):BUY:Thestock’stotalreturnoverthenext12-18monthsisexpectedtoexceedthereturnofitsrelevantbroadmarketbenchmark,asindicatedbelow.NEUTRAL:Thestock’stotalreturnoverthenext12-18monthsisexpectedtobeinlinewiththereturnofitsrelevantbroadmarketbenchmark,asindicatedbelow.ForpurposesonlyofFINRA/NYSEratingsdistributionrules,ourNeutralratingfallsintoaholdratingcategory.SELL:Thestock’stotalreturnoverthenext12-18monthsisexpectedtobebelowthereturnofitsrelevantbroadmarketbenchmark,asindicatedbelow.Benchmarksforeachstock’slistedregionareasfollows:Japan–TOPIX,Korea–KOSPI,Taiwan–TAIEX,India–Nifty100;forallotherChina-conceptstocks–MSCIChina.海通國(guó)際非評(píng)級(jí)研究：海通國(guó)際發(fā)布計(jì)量、篩選或短篇報(bào)告，并在報(bào)告中根據(jù)估值和其他指標(biāo)對(duì)股票進(jìn)行排名，或者基于可能的估值倍數(shù)提出建議價(jià)格。這種排名或建議價(jià)格并非為了進(jìn)行股票評(píng)級(jí)、提出目標(biāo)價(jià)格或進(jìn)行基本面估值，而僅供參考使用。HaitongInternationalNon-RatedResearch:HaitongInternationalpublishesquantitative,screeningorshortreportswhichmayrankstocksaccordingtovaluationandothermetricsormaysuggestpricesbasedonpossiblevaluationmultiples.Suchrankingsorsuggestedpricesdonotpurporttobestockratingsortargetpricesorfundamentalvaluesandareforinformationonly.海通國(guó)際A股覆蓋：海通國(guó)際可能會(huì)就滬港通及深港通的中國(guó)A股進(jìn)行覆蓋及評(píng)級(jí)。海通證券（600837.CH），海通國(guó)際于上海的母公司，也會(huì)于中國(guó)發(fā)布中國(guó)A股的研究報(bào)告。但是，海通國(guó)際使用與海通證券不同的評(píng)級(jí)系統(tǒng)，所以海通國(guó)際與海通證券的中國(guó)A股評(píng)級(jí)可能有所不同。HaitongInternationalCoverageofA-Shares:HaitongInternationalmaycoverandrateA-SharesthataresubjecttotheHongKongStockConnectschemewithShanghaiandShenzhen.HaitongSecurities(HS;600837CH),theultimateparentcompanyofHTISGbasedinShanghai,coversandpublishesresearchonthesesameA-SharesfordistributioninmainlandChina.However,theratingsystememployedbyHSdiffersfromthatusedbyHTIandasaresulttheremaybeadifferenceintheHTIandHSratingsforthesameA-sharestocks.海通國(guó)際優(yōu)質(zhì)100A股（Q100）指數(shù)：海通國(guó)際Q100指數(shù)是一個(gè)包括100支由海通證券覆蓋的優(yōu)質(zhì)中國(guó)A股的計(jì)量產(chǎn)品。這些股票是通過(guò)基于質(zhì)量的篩選過(guò)程，并結(jié)合對(duì)海通證券A股團(tuán)隊(duì)自下而上的研究。海通國(guó)際每季對(duì)Q100指數(shù)成分作出復(fù)審。HaitongInternationalQuality100A-share(Q100)Index:HTI’sQ100Indexisaquantproductthatconsistsof100ofthehighest-qualityA-sharesundercoverageatHSinShanghai.Thesestocksarecarefullyselectedthroughaquality-basedscreeningprocessincombinationwithareviewoftheHSA-shareteam’sbottom-upresearch.TheQ100constituentcompaniesarereviewedquarterly.盟浪義利（FIN-ESG）數(shù)據(jù)通免責(zé)聲明條款：在使用盟浪義利（FIN-ESG）數(shù)據(jù)之前，請(qǐng)務(wù)必仔細(xì)閱讀本條款并同意本聲明：第一條義利（FIN-ESG）數(shù)據(jù)系由盟浪可持續(xù)數(shù)字科技有限責(zé)任公司（以下簡(jiǎn)稱“本公司”）基于合法取得的公開(kāi)信息評(píng)估而成，本公司對(duì)信息的準(zhǔn)確性及完整性不作任何保證。對(duì)公司述的評(píng)估結(jié)果造成的任何直接或間接損失負(fù)責(zé)。第二條盟浪并不因收到此評(píng)估數(shù)據(jù)而將收件人視為客戶，收件人使用此數(shù)據(jù)時(shí)應(yīng)根據(jù)自身實(shí)際情況作出自我獨(dú)立判斷。本數(shù)據(jù)所載內(nèi)容反映的是盟浪在最初發(fā)布本數(shù)據(jù)日期當(dāng)日的判斷，盟浪有權(quán)在不發(fā)出通知的情況下更新、修訂與發(fā)出其他與本數(shù)據(jù)所載內(nèi)容不一致或有不同結(jié)論的數(shù)據(jù)。除非另行說(shuō)明，本數(shù)據(jù)（如財(cái)務(wù)業(yè)績(jī)數(shù)據(jù)等）僅代表過(guò)往表現(xiàn)，過(guò)往的業(yè)績(jī)表現(xiàn)不作為日后回報(bào)的預(yù)測(cè)。第三條本數(shù)據(jù)版權(quán)歸本公司所有，本公司依法保留各項(xiàng)權(quán)利。未經(jīng)本公司事先書(shū)面許可授權(quán)，任何個(gè)人或機(jī)構(gòu)不得將本數(shù)據(jù)中的評(píng)估結(jié)果用于任何營(yíng)利性目的，不得對(duì)本數(shù)據(jù)進(jìn)行修改、復(fù)制、編譯、匯編、再次編輯、改編、刪減、縮寫、節(jié)選、發(fā)行、出租、展覽、表演、放映、廣播、信息網(wǎng)絡(luò)傳播、攝制、增加圖標(biāo)及說(shuō)明等，否則因此給盟浪或其他第三方造成損失的，由用戶承擔(dān)相應(yīng)的賠償責(zé)任，盟浪不承擔(dān)責(zé)任。第四條如本免責(zé)聲明未約定，而盟浪網(wǎng)站平臺(tái)載明的其他協(xié)議內(nèi)容（如《盟浪網(wǎng)站用戶注冊(cè)協(xié)議》《盟浪網(wǎng)用戶服務(wù)（含認(rèn)證）協(xié)議》《盟浪網(wǎng)隱私政策》等）有約定的，則按其他協(xié)議的約定執(zhí)行；若本免責(zé)聲明與其他協(xié)議約定存在沖突或不一致的，則以本免責(zé)聲明約定為準(zhǔn)。SusallWaveFIN-ESGDataServiceDisclaimer:PleasereadthesetermsandconditionsbelowcarefullyandconfirmyouragreementandacceptancewiththesetermsbeforeusingSusallWaveFIN-ESGDataService.FIN-ESGDataisproducedbySusallWaveDigitalTechnologyCo.,Ltd.(Inshort,SusallWave)’sassessmentbasedonlegalpubliclyaccessibleinformation.SusallWaveshallnotberesponsibleforanyaccuracyandcompletenessoftheinformation.Theassessmentresultisforreferenceonly.Itisnotforanyinvestmentadviceforanyindividualorinstitutionandnotforbasisofpurchasing,sellingorholdinganyrelativefinancialproducts.WewillnotbeliableforanydirectorindirectlossofanyindividualorinstitutionasaresultofusingSusallWaveFIN-ESGData.SusallWavedonotconsiderrecipientsascustomersforreceivingthesedata.Whenusingthedata,recipientsshallmakeyourownindependentjudgmentaccordingtoyourpracticalindividualstatus.Thecontentsofthedatareflectthejudgmentofusonlyonthereleaseday.Wehaverighttoupdateandamendthedataandreleaseotherdatathatcontainsinconsistentcontentsordifferentconclusionswithoutnotification.Unlessexpresslystated,thedata(e.g.,financialperformancedata)representspastperformanceonlyandthepastperformancecannotbeviewedasthepredictionoffuturereturn.TheofthisdatabelongstoSusallWave,andwereserveallrightsinaccordancewiththelaw.Withoutthepriorwrittenpermissionofourcompany,noneofindividualorinstitutioncanusethesedataforanyprofitablepurpose.Besides,noneofindividualorinstitutioncantakeactionssuchasamendment,replication,translation,compilation,re-editing,adaption,deletion,abbreviation,excerpts,issuance,rent,exhibition,performance,projection,broadcast,informationnetworktransmission,shooting,addingiconsandinstructions.IfanylossofSusallWaveoranythird-partyiscausedbythoseactions,usersshallbearthecorrespondingcompensationliability.SusallWaveshallnotberesponsibleforanyloss.Ifanytermisnotcontainedinthisdisclaimerbutwritteninotheragreementsonourwebsite(e.g.UserRegistrationProtocolofSusallWaveWebsite,UserService(includingauthentication)AgreementofSusallWaveWebsite,PrivacyPolicyofSusallwaveWebsite),itshouldbeexecutedaccordingtootheragreements.Ifthereisanydifferencebetweenthisdisclaimandotheragreements,thisdisclaimershallbeapplied.重要免責(zé)聲明：非印度證券的研究報(bào)告：本報(bào)告由海通國(guó)際證券集團(tuán)有限公司（“HTISGL”）的全資附屬公司海通國(guó)際研究有限公司（“HTIRL”）發(fā)行，該公司是根據(jù)香港證券及期貨條例（第571章）持有第4類受規(guī)管活動(dòng)（就證券提供意見(jiàn)）HTISGLHaitongInternational(JapanK.K.（“HTIJKK”）的協(xié)助下發(fā)行，HTIJKK是由日本關(guān)東財(cái)務(wù)局監(jiān)管為投資顧問(wèn)。印度證券的研究報(bào)告：SecuritiesandExchangeBoardofIndia（“SEBI”）監(jiān)管的HaitongSecuritiesIndiaPrivateLimited（“HTSIPL”）所發(fā)BSELimited（“BSE”）和NationalStockExchangeofIndiaLimited（“NSE”）上市公司（統(tǒng)稱為「印度交易所」）的研究報(bào)告。HTSIPL于2016年1222日被收購(gòu)并成為海通國(guó)際證券集團(tuán)有限公司（“HTISG”）的一部分。所有研究報(bào)告均以海通國(guó)際為名作為全球品牌，經(jīng)許可由海通國(guó)際證券股份有限公司及/或海通國(guó)際證券集團(tuán)的其他成員在其司法管轄區(qū)發(fā)布。本文件所載信息和觀點(diǎn)已被編譯或源自可靠來(lái)源，但HTIRL、HTISCL或任何其他屬于海通國(guó)際證券集團(tuán)有限公司（“HTISG”）的成員對(duì)其準(zhǔn)確性、完整性和正確性不做任何明示或暗示的聲明或保證。本文件中所有觀點(diǎn)均截至本報(bào)告日期，如有更改，恕不另行通知。本文件僅供參考使用。文件中提及的任何公司或其股票的說(shuō)明并非意圖展示完整的內(nèi)容，本文件并非/不應(yīng)被解釋為對(duì)證券買賣的明示或暗示地出價(jià)或征價(jià)。在某些司法管轄區(qū)，本文件中提及的證券可能無(wú)法進(jìn)行買賣。如果投資產(chǎn)品以投資者本國(guó)貨幣以外的幣種進(jìn)行計(jì)價(jià)，則匯率變化可能會(huì)對(duì)投資產(chǎn)生不利影響。過(guò)去的表現(xiàn)并不一定代表將來(lái)的結(jié)果。某些特定交易，包括設(shè)計(jì)金融衍生工具的，有產(chǎn)生重大風(fēng)險(xiǎn)的可能性，因此并不適合所有的投資者。您還應(yīng)認(rèn)識(shí)到本文件中的建議并非為您量身定制。分析師并未考慮到您自身的財(cái)務(wù)情況，如您的財(cái)務(wù)狀況和風(fēng)險(xiǎn)偏好。因此您必須自行分析并在適用的情況下咨詢自己的法律、稅收、會(huì)計(jì)、金融和其他方面的專業(yè)顧問(wèn)，以期在投資之前評(píng)估該項(xiàng)建議是否適合于您。若由于使用本文件所載的材料而產(chǎn)生任何直接或間接的損失，HTISG及其董事、雇員或代理人對(duì)此均不承擔(dān)任何責(zé)任。除對(duì)本文內(nèi)容承擔(dān)責(zé)任的分析師除外，HTISG及我們的關(guān)聯(lián)公司、高級(jí)管理人員、董事和雇員，均可不時(shí)作為主事人就本文件所述的任何證券或衍生品持有長(zhǎng)倉(cāng)或短倉(cāng)以及進(jìn)行買賣。HTISG的銷售員、交易員和其他專業(yè)人士均可向HTISG的相關(guān)客戶和公司提供與本文件所述意見(jiàn)相反的口頭或書(shū)面市場(chǎng)評(píng)論意見(jiàn)或交易策略。HTISG可做出與本文件所述建議或意見(jiàn)不一致的投資決策。但HTIRL沒(méi)有義務(wù)來(lái)確保本文件的收件人了解到該等交易決定、思路或建議。請(qǐng)?jiān)L問(wèn)海通國(guó)際網(wǎng)站，查閱更多有關(guān)海通國(guó)際為預(yù)防和避免利益沖突設(shè)立的組織和行政安排的內(nèi)容信息。非美國(guó)分析師披露信息：本項(xiàng)研究首頁(yè)上列明的海通國(guó)際分析師并未在FINRA進(jìn)行注冊(cè)或者取得相應(yīng)的資格，并且不受美國(guó)FINRA有關(guān)與本項(xiàng)研究目標(biāo)公司進(jìn)行溝通、公開(kāi)露面和自營(yíng)證券交易的第2241條規(guī)則之限制。IMPORTANTDISCLAIMERForresearchreportsonnon-Indiansecurities:TheresearchreportisissuedbyHaitongInternationalResearchLimited(“HTIRL”),awhollyownedsubsidiaryofHaitongInternationalSecuritiesGroupLimited(“HTISGL”)andalicensedcorporationtocarryonType4regulatedactivity(advisingonsecurities)forthepurposeoftheSecuritiesandFuturesOrdinance(Cap.571)ofHongKong,withtheassistanceofHaitongInternational(Japan)K.K.(“HTIJKK”),awhollyownedsubsidiaryofHTISGLandwhichisregulatedasanInvestmentAdviserbytheKantoFinanceBureauofJapan.ForresearchreportsonIndiansecurities:TheresearchreportisissuedbyHaitongSecuritiesIndiaPrivateLimited(“HSIPL”),anIndiancompanyandaSecuritiesandExchangeBoardofIndia(“SEBI”)registeredStockBroker,MerchantBankerandResearchAnalystthat,interalia,producesanddistributesresearchreportscoveringlistedentitiesontheBSELimited(“BSE”)andtheNationalStockExchangeofIndiaLimited(“NSE”)(collectivelyreferredtoas“IndianExchanges”).HSIPLwasacquiredandbecamepartoftheHaitongInternationalSecuritiesGroupofCompanies(“HTISG”)on22December2016.AlltheresearchreportsaregloballybrandedunderthenameHaitongInternationalandapprovedfordistributionbyHaitongInternationalSecuritiesCompanyLimited(“HTISCL”)and/oranyothermemberswithinHTISGintheirrespectivejurisdictions.Theinformationandopinionscontainedinthisresearchreporthavebeencompiledorarrivedatfromsourcesbelievedtobereliableandingoodfaithbutnorepresentationorwarranty,expressorimplied,ismadebyHTIRL,HTISCL,HSIPL,HTIJKKoranyothermemberswithinHTISGfromwhichthisresearchreportmaybereceived,astotheiraccuracy,completenessorcorrectness.Allopinionsexpressedhereinareasofthedateofthisresearchreportandaresubjecttochangewithoutnotice.Thisresearchreportisforinformationpurposeonly.Descriptionsofanycompaniesortheirsecuritiesmentionedhereinarenotintendedtobecompleteandthisresearchreportisnot,andshouldnotbeconstruedexpresslyorimpliedlyas,anoffertobuyorsellsecurities.Thesecuritiesreferredtointhisresearchreportmaynotbeeligibleforpurchaseorsaleinsomejurisdictions.Ifaninvestmentproductisdenominatedinacurrencyotherthananinvestor'shomecurrency,achangeinexchangeratesmayadverselyaffecttheinvestment.Pastperformanceisnotnecessarilyindicativeoffutureresults.Certaintransactions,includingthoseinvolvingderivatives,giverisetosubstantialriskandarenotsuitableforallinvestors.Youshouldalsobearinmindthatrecommendationsinthisresearchreportarenottailor-madeforyou.Theanalysthasnottakenintoaccountyouruniquefinancialcircumstances,suchasyourfinancialsituationandriskappetite.Youmust,therefore,analyzeandshould,whereapplicable,consultyourownlegal,tax,accounting,financialandotherprofessionaladviserstoevaluatewhethertherecommendationssuitsyoubeforeinvestment.NeitherHTISGnoranyofitsdirectors,employeesoragentsacceptsanyliabilitywhatsoeverforanydirectorconsequentiallossarisingfromanyuseofthematerialscontainedinthisresearchreport.HTISGandouraffiliates,officers,directors,andemployees,excludingtheanalystsresponsibleforthecontentofthisdocument,willfromtimetotimehavelongorshortpositionsin,actasprincipalin,andbuyorsell,thesecuritiesorderivatives,ifany,referredtointhisresearchreport.Sales,traders,andotherprofessionalsofHTISGmayprovideoralorwrittenmarketcommentaryortradingstrategiestotherelevantclientsandthecompanieswithinHTISGthatreflectopinionsthatarecontrarytotheopinionsexpressedinthisresearchreport.HTISGmaymakeinvestmentdecisionsthatareinconsistentwiththerecommendationsorviewsexpressedinthisresearchreport.HTIisundernoobligationtoensurethatsuchothertradingdecisions,ideasorrecommendationsarebroughttotheattentionofanyrecipientofthisresearchreport.PleaserefertoHTI’swebsiteforfurtherinformationonHTI’sorganizationalandadministrativearrangementssetupforthepreventionandavoidanceofconflictsofinterestwithrespecttoResearch.NonU.S.AnalystDisclosure:TheHTIanalyst(s)listedonthecoverofthisResearchis(are)notregisteredorqualifiedasaresearchanalystwithFINRAandarenotsubjecttoU.S.FINRARule2241restrictionsoncommunicationswithcompaniesthatarethesubjectoftheResearch;publicappearances;andtradingsecuritiesbyaresearchanalyst.分發(fā)和地區(qū)通知：除非下文另有規(guī)定，否則任何希望討論本報(bào)告或者就本項(xiàng)研究中討論的任何證券進(jìn)行任何交易的收件人均應(yīng)聯(lián)系其所在國(guó)家或地區(qū)的海通國(guó)際銷售人員。香港投資者的通知事項(xiàng)：海通國(guó)際證券股份有限公司(“HTISCL”)負(fù)責(zé)分發(fā)該研究報(bào)告，HTISCL1類受規(guī)管活動(dòng)（從事證券交易）的持牌公司。該研究報(bào)告并不構(gòu)成《證券及期貨條例》（571章）（以下簡(jiǎn)稱“SFO”）SFO所界定的“專業(yè)投資者”。本研究報(bào)告未經(jīng)過(guò)證券及期貨事務(wù)監(jiān)察委員會(huì)的審查。您不應(yīng)僅根據(jù)本研究報(bào)告中所載的信息做出投資決定。本研究報(bào)告的收件人就研究報(bào)告中產(chǎn)生或與之相關(guān)的任何事宜請(qǐng)聯(lián)系HTISCL銷售人員。美國(guó)投資者的通知事項(xiàng)：HTIRL，HSIPLHTIJKKHTIRL，HSIPL，HTIJKKHTISG美國(guó)聯(lián)營(yíng)公司，均未在美國(guó)注冊(cè)，因此不受美國(guó)關(guān)于研究報(bào)告編制和研1934年“美國(guó)證券交易法”第15a-6條規(guī)定的豁免注冊(cè)的「美國(guó)主要機(jī)構(gòu)投資者」（“MajorU.SInstitutionalInvestor”）和「機(jī)構(gòu)投資者」（”U.SInstitutionalInvestors”）。在向美國(guó)機(jī)構(gòu)投資者分發(fā)研究報(bào)告時(shí)，HaitongInternationalSecuritiesUSAInc（“HTIUSA”）HTIUSA。HTIUSA340MadisonAvenue,12thFloorNewYorkNY10173，電話（212）351-6050。HTIUSAU.SSecuritiesandExchangeCommission（“SEC”）FinancialIndustryRegulatoryAuthorityInc.（“FINRA”）的成員。HTIUSA不負(fù)責(zé)編寫HSIPL，HTIRLHTIJKK直接進(jìn)行買賣證券或相HSIPL，HTIRLHTIJKKFINRAFINRA2241條規(guī)定的與目標(biāo)公司的交流，公開(kāi)露面和分析師賬戶持有的交易證券等限制。投資本研究報(bào)告中討論的任何非美國(guó)證券或相關(guān)金融工具（包括ADR）可能存在一定風(fēng)險(xiǎn)。非美國(guó)發(fā)行的證券可能沒(méi)有注冊(cè)，或不受美國(guó)法規(guī)的約束。有關(guān)非美國(guó)證券或相關(guān)金融工具的信息可能有限制。外國(guó)公司可能不受審計(jì)和匯報(bào)的標(biāo)準(zhǔn)以及與美國(guó)境內(nèi)生效相符的監(jiān)管要求。本研究報(bào)告中以美元以外的其他貨幣計(jì)價(jià)的任何證券或相關(guān)金融工具的投資或收益的價(jià)值受匯率波動(dòng)的影響，可能對(duì)該等證券或相關(guān)金融工具的價(jià)值或收入產(chǎn)生正面或負(fù)面影響。美國(guó)收件人的所有問(wèn)詢請(qǐng)聯(lián)系：HaitongInternationalSecurities(USA)Inc.340MadisonAvenue,12thFloorNewYork,NY10173聯(lián)系人電話：(212)3516050DISTRIBUTIONANDREGIONALNOTICESExceptasotherwiseindicatedbelow,anyRecipientwishingtodiscussthisresearchreportoreffectanytransactioninanysecuritydiscussedinHTI’sresearchshouldcontacttheHaitongInternationalsalespersonintheirowncountryorregion.NoticetoHongKonginvestors:TheresearchreportisdistributedbyHaitongInternationalSecuritiesCompanyLimited(“HTISCL”),whichisalicensedcorporationtocarryonType1regulatedactivity(dealinginsecurities)inHongKong.ThisresearchreportdoesnotconstituteasolicitationoranofferofsecuritiesoraninvitationtothepublicwithinthemeaningoftheSFO.Thisresearchreportisonlytobecirculatedto"ProfessionalInvestors"asdefinedintheSFO.ThisresearchreporthasnotbeenreviewedbytheSecuritiesandFuturesCommission.Youshouldnotmakeinvestmentdecisionssolelyonthebasisoftheinformationcontainedinthisresearchreport.RecipientsofthisresearchreportaretocontactHTISCLsalespersonsinrespectofanymattersarisingfrom,orinconnectionwith,theresearchreport.NoticetoU.S.investors:Asdescribedabove,thisresearchreportwaspreparedbyHTIRL,HSIPLorHTIJKK.NeitherHTIRL,HSIPL,HTIJKK,noranyofthenonU.S.HTISGaffiliatesisregisteredintheUnitedStatesand,therefore,isnotsubjecttoU.S.rulesregardingthepreparationofresearchreportsandtheindependenceofresearchanalysts.Thisresearchreportisprovidedfordistributionto“majorU.S.institutionalinvestors”and“U.S.institutionalinvestors”inrelianceontheexemptionfromregistrationprovidedbyRule15a-6oftheU.S.SecuritiesExchangeActof1934,asamended.Whendistributingresearchreportsto“U.S.institutionalinvestors,”HTIUSAwillaccepttheresponsibilitiesforthecontentofthereports.AnyU.S.recipientofthisresearchreportwishingtoeffectanytransactiontobuyorsellsecuritiesorrelatedfinancialinstrumentsbasedontheinformationprovidedinthisresearchreportshoulddosoonlythroughHaitongInternationalSecurities(USA)Inc.(“HTIUSA”),locatedat340MadisonAvenue,12thFloor,NewYork,NY10173,USA;telephone(212)3516050.HTIUSAisabroker-dealerregisteredintheU.S.withtheU.S.SecuritiesandExchangeCommission(the“SEC”)andamemberoftheFinancialIndustryRegulatoryAuthority,Inc.(“FINRA”).HTIUSAisnotresponsibleforthepreparationofthisresearchreportnorfortheanalysiscontainedtherein.UndernocircumstancesshouldanyU.S.recipientofthisresearchreportcontacttheanalystdirectlyoreffectanytransactiontobuyorsellsecuritiesorrelatedfinancialinstrumentsdirectlythroughHSIPL,HTIRLorHTIJKK.TheHSIPL,HTIRLorHTIJKKanalyst(s)whosenameappearsinthisresearchreportisnotregisteredorqualifiedasares